ABAndrea Beharry

Andrea Beharry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Beharry has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer

    by Roger Ferreira, Kassandra R. Bisson, Andrea Beharry, Champica Nicholas, Marco Iafolla, Samir Bidnur, Brandon S. Sheffield

    Background/Objectives: Ataxia telangiectasia-mutated kinase is encoded by the ATM gene. This gene is altered in many cancer types; however, it is most relevant for eligibility of poly-ADP-ribose polymerase inhibitor (PARPi) therapy in metastatic castrate-resistant prostate cancer in Canada. Non-benign ATM alterations are relatively uncommon, seen in less than 10% of prostate cancers; however, many of these are variants of uncertain significance with limited evidence of clinical significance or actionability. Methods: To aid in variant classification of next-generation sequencing results, ATM immunohistochemistry (IHC) is performed on patient tumour samples to serve as patient-specific functional evidence for ATM protein loss. Results: ATM IHC demonstrates strong concordance with known loss-of-function variants and copy number losses. Additionally, it can be used to clarify ATM protein loss in cases involving variants of uncertain significance (VUSs) or copy number deletions. Conclusions: Incorporation of ATM IHC into clinical testing for prostate cancer represents a relatively cost-effective orthogonal approach that can rescue poor-quality NGS results and clarify the functional impact of ATM VUSs on protein expression. Overall, this strategy may provide useful supportive evidence in prostate cancer biomarker testing and interpretation.

  • Open Access

    Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center

    by Champica Nicholas, Andrea Beharry, Anna M. Bendzsak, Kassandra R. Bisson, Keith Dadson, Shaan Dudani, Marco Iafolla, Kashif Irshad, Kirstin Perdrizet, William Raskin, et al.

    Liquid biopsy is rapidly becoming an indispensable tool in the oncologist’s arsenal; however, this technique remains elusive in a publicly funded healthcare system, and real-world evidence is needed to demonstrate utility and feasibility. Here, we describe the first experience of an in-house point of care liquid biopsy program at a Canadian community hospital. A retrospective review of consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. Liquid biopsy was initiated at the discretion of clinicians. Sequencing followed a point of care workflow using the Genexus™ integrated sequencer and the Oncomine precision assay, performed by histotechnologists. Results were reported by the attending pathologist. Eligible charts were reviewed for outcomes of interest, including the intent of the liquid biopsy, results of the liquid biopsy, and turnaround time from blood draw to results available. A total of 124 cases, with confirmed or suspected cancer, underwent liquid biopsy between January 2021 and November 2023. The median turnaround time for liquid biopsy results was 3 business days (range 1–12 days). The sensitivity of liquid biopsies was 71%, compared to tissue testing in cases with matched tissue results available for comparison. Common mutations included EGFR (29%), in 86 lung cancer patients, and PIK3CA (22%), identified in 13 breast cancer patients. Healthcare providers ordered liquid biopsies to inform diagnostic investigations and treatment decisions, and to determine progression or resistance mechanisms, as these reasons often overlapped. This study demonstrates that rapid in-house liquid biopsy using point of care methodology is feasible. The technique facilitates precision treatment and offers many additional advantages for cancer care.


  • Open Access

    Reply to Torlakovic, E.; Normanno, N. Comment on “Bisson et al. Novel Approach to Proficiency Testing Highlights Key Practice Variations in Cancer Biomarker Delivery. J. Mol. Pathol. 2024, 5, 1–10”

    by Brandon S. Sheffield, Kassandra R. Bisson, Andrea Beharry, Michael D. Carter, Shaan Dudani, Jonathan M. Loree, Stephanie Snow, Jennifer R. Won, Stephen Yip, John G. Garratt

  • Open Access

    Novel Approach to Proficiency Testing Highlights Key Practice Variations in Cancer Biomarker Delivery

    by Kassandra R. Bisson, Jennifer R. Won, Andrea Beharry, Michael D. Carter, Shaan Dudani, John G. Garratt, Jonathan M. Loree, Stephanie Snow, Stephen Yip, Brandon S. Sheffield

    Biomarkers are fundamental to modern oncology practice, forming a close link to pathology practice. Pathology results must be accurate, timely, comprehensive, and comprehendible. External proficiency testing is a key tool in maintaining biomarker quality. Here, we demonstrate the feasibility and utility of a novel end-to-end proficiency testing exercise exploring accuracy, turnaround time, and communication. Challenge specimens were made using resected colon cancer tissue, each paired with a fictional clinical vignette, and distributed to participants who were asked to provide all molecular testing required and return a final report for each case upon completion. Reports were redistributed to an assessor team including medical oncologists, each of whom was asked to recommend a systemic therapy based on each lab’s biomarker report. Participants were graded based on their ability to guide oncologists to the correct treatment. Eight laboratories participated. Three laboratories were found to have suboptimal results, two leading oncologists to incorrect therapeutic prescriptions, and one withdrawn. Turnaround time ranged from 6 to 86 days (median 24). Substantial qualitative reporting differences were identified. This study demonstrates the feasibility of end-to-end proficiency testing. The approach provides considerable value beyond analytic accuracy, including specimen management, turnaround time, and communication of results. Results suggest that reporting differences may lead to treatment disparities. This style of quality assurance will help reinforce good practices critical to the delivery of precision cancer care.


  • Open Access

    Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care

    by Brandon S. Sheffield, Andrea Beharry, Joanne Diep, Kirstin Perdrizet, Marco A. J. Iafolla, William Raskin, Shaan Dudani, Mary Anne Brett, Blerta Starova, Brian Olsen, et al.

    Purpose: Biomarker data are critical to the delivery of precision cancer care. The average turnaround of next-generation sequencing (NGS) reports is over 2 weeks, and in-house availability is typically limited to academic centers. Lengthy turnaround times for biomarkers can adversely affect outcomes. Traditional workflows involve moving specimens through multiple facilities. This study evaluates the feasibility of rapid comprehensive NGS using the Genexus integrated sequencer and a novel streamlined workflow in a community setting. Methods: A retrospective chart review was performed to assess the early experience and performance characteristics of a novel approach to biomarker testing at a large community center. This approach to NGS included an automated workflow utilizing the Genexus integrated sequencer, validated for clinical use. NGS testing was further integrated within a routine immunohistochemistry (IHC) service, utilizing histotechnologists to perform technical aspects of NGS, with results reported directly by anatomic pathologists. Results: Between October 2020 and October 2021, 578 solid tumor samples underwent genomic profiling. Median turnaround time for biomarker results was 3 business days (IQR: 2–5). Four hundred eighty-one (83%) of the cases were resulted in fewer than 5 business days, and 66 (11%) of the cases were resulted simultaneously with diagnosis. Tumor types included lung cancer (310), melanoma (97), and colorectal carcinoma (68), among others. NGS testing detected key driver alterations at expected prevalence rates: lung EGFR (16%), ALK (3%), RET (1%), melanoma BRAF (43%), colorectal RAS/RAF (67%), among others. Conclusion: This is the first study demonstrating clinical implementation of rapid NGS. This supports the feasibility of automated comprehensive NGS performed and interpreted in parallel with diagnostic histopathology and immunohistochemistry. This novel approach to biomarker testing offers considerable advantages to clinical cancer care.